Chengdu Easton Biopharmaceuticals Co., Ltd. Class ASSE: 688513

"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Implementation Results of Share Repurchase

Sep 4, 2026 · Issued by Chengdu Easton Biopharmaceuticals Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Implementation Results of Share Repurchase

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Chengdu Easton Biopharmaceuticals Co., Ltd. Class A

"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Progress in Repurchasing SharesSep 1
"Chengdu Easton Bio Pharmaceuticals Co., Ltd."Notice on Convening the 2nd Extraordinary General Meeting in 2026Aug 21
"Chengdu Easton Bio Pharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of the Initiation of Phase I/II Clinical Trial for HP-002 Tablets and Completion of First Subject Enrollment and DosingAug 13
"Chengdu Easton Bio Pharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Proposed Selection in the National Centralized Drug ProcurementAug 4

All Chengdu Easton Biopharmaceuticals Co., Ltd. Class A news releases